IFNL3 and hepatitis C virus infection: The Japanese guidelines for the management of hepatitis C virus infection [1] recommend that analysis of IL28B SNP and amino acid substitution at core 70 should be performed to enable selection of the optimum therapy regimen; telaprevir-based triple therapy is not recommended in patients with both the IL28B minor allele and mutant type of amino acid substitution at core 70.